ADAM9

Summary

ADAM9 (ADAM metallopeptidase domain 9, HGNC:216) is a protein-coding gene on chromosome 8p11.22, encoding Disintegrin and metalloproteinase domain-containing protein 9 (Q13443). Metalloprotease that cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5.

This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The protein encoded by this gene interacts with SH3 domain-containing proteins, binds mitotic arrest deficient 2 beta protein, and is also involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. Several alternatively spliced transcript variants have been identified for this gene.

Source: NCBI Gene 8754 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ADAM9-related retinopathy (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 1
• Clinical variants (ClinVar): 599 total — 23 pathogenic, 9 likely-pathogenic
• Phenotypes (HPO): 17
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_003816

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:216
Approved symbol	ADAM9
Name	ADAM metallopeptidase domain 9
Location	8p11.22
Locus type	gene with protein product
Status	Approved
Aliases	MDC9, KIAA0021, MCMP, Mltng
Ensembl gene	ENSG00000168615
Ensembl biotype	protein_coding
OMIM	602713
Entrez	8754

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 15 nonsense_mediated_decay, 13 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000379917, ENST00000463437, ENST00000466936, ENST00000468065, ENST00000481058, ENST00000481513, ENST00000481873, ENST00000484143, ENST00000487273, ENST00000676489, ENST00000676617, ENST00000676643, ENST00000676669, ENST00000676765, ENST00000676919, ENST00000676936, ENST00000677004, ENST00000677137, ENST00000677165, ENST00000677359, ENST00000677582, ENST00000677908, ENST00000678253, ENST00000678474, ENST00000678540, ENST00000678730, ENST00000678863, ENST00000679268, ENST00000893524, ENST00000893525, ENST00000893526, ENST00000893527, ENST00000966952

RefSeq mRNA: 1 — MANE Select: NM_003816 NM_003816

CCDS: CCDS6112

Canonical transcript exons

ENST00000487273 — 22 exons

Exon	Start	End
ENSE00001129032	39082641	39082721
ENSE00001129038	39071298	39071403
ENSE00001129046	39055577	39055772
ENSE00001155308	39026677	39026810
ENSE00001155318	39025803	39025884
ENSE00001155326	39023156	39023325
ENSE00001155336	39021643	39021714
ENSE00001155346	39017219	39017414
ENSE00001155353	39016118	39016194
ENSE00001157032	39041946	39042117
ENSE00001196585	39082968	39083073
ENSE00001274312	39054481	39054573
ENSE00001274364	39013965	39014043
ENSE00001274374	39011658	39011716
ENSE00001274383	39007886	39007983
ENSE00001882322	39103607	39105261
ENSE00003467627	39091259	39091346
ENSE00003476366	39101863	39101930
ENSE00003610635	39077228	39077411
ENSE00003642615	39090047	39090188
ENSE00003644662	39018853	39018918
ENSE00003845718	38996973	38997160

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 98.35.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 79.1277 / max 1133.3668, expressed in 1819 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
88571	71.7903	1795
88569	3.8523	1255
88568	2.3438	1262
88570	0.9863	617
88575	0.1551	67

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	98.35	gold quality
islet of Langerhans	UBERON:0000006	97.59	gold quality
gall bladder	UBERON:0002110	96.99	gold quality
smooth muscle tissue	UBERON:0001135	96.42	gold quality
right lung	UBERON:0002167	96.29	gold quality
descending thoracic aorta	UBERON:0002345	95.62	gold quality
thoracic aorta	UBERON:0001515	95.33	gold quality
calcaneal tendon	UBERON:0003701	95.33	gold quality
ascending aorta	UBERON:0001496	95.29	gold quality
upper lobe of left lung	UBERON:0008952	95.18	gold quality
rectum	UBERON:0001052	95.09	gold quality
right coronary artery	UBERON:0001625	94.98	gold quality
minor salivary gland	UBERON:0001830	94.96	gold quality
vermiform appendix	UBERON:0001154	94.45	gold quality
upper lobe of lung	UBERON:0008948	94.42	gold quality
body of stomach	UBERON:0001161	94.34	gold quality
left coronary artery	UBERON:0001626	94.26	gold quality
aorta	UBERON:0000947	94.25	gold quality
popliteal artery	UBERON:0002250	93.85	gold quality
tibial artery	UBERON:0007610	93.85	gold quality
adrenal tissue	UBERON:0018303	93.79	gold quality
ventricular zone	UBERON:0003053	93.63	gold quality
tendon	UBERON:0000043	93.03	gold quality
colonic epithelium	UBERON:0000397	93.02	gold quality
buccal mucosa cell	CL:0002336	92.65	gold quality
stomach	UBERON:0000945	92.41	gold quality
left adrenal gland	UBERON:0001234	92.40	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.31	gold quality
left adrenal gland cortex	UBERON:0035825	92.19	gold quality
heart left ventricle	UBERON:0002084	92.17	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	11.53
E-ANND-3	yes	7.52

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR

miRNA regulators (miRDB)

157 targeting ADAM9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-570-3P	99.96	72.41	4910

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• ADAM9 is involved in monocyte fusion. (PMID:11831872)
• The downregulated expression of ADAM9 may serve as a marker for anterior polar cataracts. (PMID:11955914)
• cloning of a novel form of human ADAM9 (hADAM9s) which has an alpha-secretase activity for Amyloid Protein Precursor (PMID:12054541)
• First evidence is presented of ADAM9 as an insulin-like growth factor binding protein-5 (IGFBP-5) protease produced and secreted by osteoblasts in culture, able to degrade IGFBP-5 with high potency, thereby regulating the critical activity of IGFBP-5. (PMID:12484779)
• The results indicate that ADAM9, ADAM10, and ADAM17, members of the disintegrin and metalloprotease family, catalyze alpha-secretory cleavage and therefore act as alpha-secretases in A172 cells. (PMID:12535668)
• Expression of ADAM-9 mRNA and protein in human breast cancer. (PMID:12767059)
• Cytoplasmic ADAM9 overexpression is associated with poor differentiation in ductal adenocarcinoma (PMID:14997207)
• ADAM9 overexpression enhances cell adhesion and invasion of non-small cell lung cancer cells via modulation of other adhesion molecules and changes in sensitivity to growth factors, thereby promoting metastatic capacity to the brain. (PMID:15205330)
• In melanoma ADAM-9 protein expression appeared to be restricted to the melanoma cells within the invading front. (PMID:15856464)
• In conclusion, our findings are consistent with the hypothesis that FHL-2 and ADAM-9 are important modulators of IGFBP-5 actions and are, in part, regulated in a coordinated manner in bone (PMID:16311053)
• ADAM9 does not behave as a genuine alpha-secretase but rather acts as an important upstream regulator of ADAM10 activity. (PMID:16806063)
• Intracellular ROS and/or hydrogen peroxide, generated by cell stress, regulate ADAM9 expression. ADAM9 may support prostate cancer cell survival and progression. (PMID:17018608)
• These findings suggest that reactive oxygen species is a common mediator responsible for ADAM9 protein induction in human prostate cancer cells, downstream from androgen receptor, and stress response signaling. (PMID:17342749)
• the ADAM-9 adhesive domain plays a role in regulating the motility of cells by interaction with beta1 integrins and modulates MMP synthesis. (PMID:17704059)
• ADAM9 is overexpressed in prostate cancer cases and is an independent prognostic marker of PSA relapse-free survival following radical prostatectomy. (PMID:18061337)
• ADAM9 plays a crucial role in UV-induced EGFR activation and is overexpressed in skin cancer cell lines (PMID:19003995)
• The data of this suggested that promoter polymorphisms which regulate ADAM9 transcription are protective against SAD. (PMID:19237226)
• involved in advanced atherosclerosis, in catalytically active form, most notably associated with cells of monocytic origin (PMID:19253070)
• Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM9/10-mediated mechanism. (PMID:19394555)
• ADAM9 is a CRD gene and also is a form of pathology wherein retinal disease first manifests at the POS-RPE junction. (PMID:19409519)
• ADAM9 expression is low in the squamous epithelium of the cervix, but is increased in CIN3 lesions as well as SCCs being the increase in both cases statistically significant. (PMID:19473694)
• the role of the disintegrin domain of the human ADAM9 (ADAM9D) on the adhesion of breast tumor cells and platelets to collagen I (PMID:19505527)
• Data show that the expression levels MMP1, MMP9, ADAM9 and TIMP3 were altered in drug-resistant sublines. (PMID:19543729)
• Experiments revealed that ADAM9 and ADAM10, but not ADAM17, are involved in the shedding of PrP(C) and that ADAM9 exerts its effect on PrP(C) shedding via ADAM10. (PMID:19564338)
• disintegrin and metalloprotease-9 is overexpressed in hepatocellular carcinoma and can be used as a prognostic marker (PMID:20388695)
• is expressed in adenoid cystic carcinoma-associated metastasis (PMID:20422344)
• ADAM9 plays a crucial role in prostate cancer progression and therapeutic resistance in part by altering E-cadherin and integrin expression. (PMID:20672324)
• Secreted variants of ADAM9 are a key determinant in manifestation of aggressive migratory phenotypes associated with breast cancer progression. (PMID:20736367)
• ADAM-9 expression plays an important role in mediating cell-cell contacts between fibroblasts and melanoma cells and that these interactions contribute to proteolytic activities required during invasion of melanoma cells. (PMID:21135106)
• ADAM10 activity is regulated by inhibition of ADAM9, and this regulation may be used to control shedding of amyloid precursor protein by enhancing alpha-secretase activity, a key regulatory step in the etiology of Alzheimer disease (PMID:21956108)
• The miR-126/ADAM9 axis plays essential role in the inhibition of invasive growth of pancreatic cancer cells. (PMID:22064652)
• Transient transfection of ADAM9 and ACE cDNAs into HEK293 cells demonstrated that ADAM9 requires both membrane anchorage and its catalytic domain to shed ACE. (PMID:22480688)
• ADAM9 expression was low in castration resistant prostate cancer (CRPC), correlated with poor prognosis and might be involved in the succession from hormonal sensitive prostate cancer (HSPC) to CRPC by various functions. (PMID:23106877)
• a novel molecular mechanism of ADAM9 in the regulation of prostate cancer cell proliferation. (PMID:23342005)
• The over-expression of MGAM was confirmed with a 6.6 fold increase in expression at the mRNA level whereas the fold change in ADAM9 demonstrated a 1.6 fold increase. (PMID:23405089)
• ADAM19 was upregulated in patients with ulcerative colitis and, to a lesser extent, in patients with Crohn’s disease compared with normal controls. In contrast, ADAM9 and ADAM10 expression did not differ between patients with IBD and controls. (PMID:23429442)
• miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. (PMID:23437250)
• ADAM9 is an important molecule in the processes of invasion and metastasis. (PMID:23499592)
• The expression of circulating ADAM9 is down-regulated in pulmonary sarcoidosis. (PMID:23857158)
• ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells. (PMID:24705471)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	adam9a	ENSDARG00000010070
mus_musculus	Adam9	ENSMUSG00000031555
rattus_norvegicus	Adam9	ENSRNOG00000017231

Paralogs (20): ADAM22 (ENSG00000008277), ADAM28 (ENSG00000042980), ADAM7 (ENSG00000069206), ADAM11 (ENSG00000073670), ADAM2 (ENSG00000104755), ADAM23 (ENSG00000114948), ADAM20 (ENSG00000134007), ADAMDEC1 (ENSG00000134028), ADAM30 (ENSG00000134249), ADAM19 (ENSG00000135074), ADAM10 (ENSG00000137845), ADAM21 (ENSG00000139985), ADAM15 (ENSG00000143537), ADAM12 (ENSG00000148848), ADAM33 (ENSG00000149451), ADAM8 (ENSG00000151651), ADAM17 (ENSG00000151694), ADAM29 (ENSG00000168594), ADAM18 (ENSG00000168619), ADAM32 (ENSG00000197140)

Protein

Protein identifiers

Disintegrin and metalloproteinase domain-containing protein 9 — Q13443 (reviewed: Q13443)

Alternative names: Cellular disintegrin-related protein, Meltrin-gamma, Metalloprotease/disintegrin/cysteine-rich protein 9, Myeloma cell metalloproteinase

All UniProt accessions (18): A0A7I2V2E1, A0A7I2V2Z6, A0A7I2V303, A0A7I2V3B5, A0A7I2V3C1, A0A7I2V3I3, A0A7I2V3W3, A0A7I2V4B3, A0A7I2V4T8, A0A7I2V5C0, A0A7I2V5N8, A0A7I2V5Q0, A0A7I2YQ97, A0AVL1, Q13443, C9J6H5, C9JPM3, F8WC54

UniProt curated annotations — full annotation on UniProt →

Function. Metalloprotease that cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5. May mediate cell-cell, cell-matrix interactions and regulate the motility of cells via interactions with integrins. May act as alpha-secretase for amyloid precursor protein (APP).

Subunit / interactions. Interacts with SH3GL2 and SNX9 through its cytoplasmic tail. Interacts with ITGA6.

Subcellular location. Cell membrane Secreted.

Tissue specificity. Widely expressed. Expressed in chondrocytes. Isoform 2 is highly expressed in liver and heart.

Post-translational modifications. Proteolytically cleaved in the trans-Golgi network before it reaches the plasma membrane to generate a mature protein. The removal of the pro-domain occurs via cleavage at two different sites. Processed most likely by a pro-protein convertase such as furin, at the boundary between the pro-domain and the catalytic domain. An additional upstream cleavage pro-protein convertase site (Arg-56/Glu-57) has an important role in the activation of ADAM9. Phosphorylation is induced in vitro by phorbol-12-myristate-13-acetate (PMA).

Disease relevance. Cone-rod dystrophy 9 (CORD9) [MIM:612775] An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Synthesized as an inactive form which is proteolytically cleaved to generate an active enzyme. Processing at the upstream site is particularly important for activation of the proenzyme, whereas processing at the boundary between the pro-domain and the catalytic domain does not appear to be essential. Inhibited by hydroxamic acid-based inhibitors.

Cofactor. Binds 1 zinc ion per subunit.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (2)

UniProt ID	Names	Canonical?
Q13443-1	1	yes
Q13443-2	2

RefSeq proteins (1): NP_003807* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR001590	Peptidase_M12B	Domain
IPR001762	Disintegrin_dom	Domain
IPR002870	Peptidase_M12B_N	Domain
IPR006586	ADAM_Cys-rich	Domain
IPR018358	Disintegrin_CS	Conserved_site
IPR024079	MetalloPept_cat_dom_sf	Homologous_superfamily
IPR034027	Reprolysin_adamalysin	Domain
IPR036436	Disintegrin_dom_sf	Homologous_superfamily

Pfam: PF00200, PF01421, PF01562, PF08516

Enzyme classification (BRENDA):

• EC 3.4.24.B9 — (BRENDA: organisms, substrates, inhibitors, Km, kcat entries)

UniProt features (41 total): disulfide bond 7, sequence conflict 7, glycosylation site 6, binding site 3, domain 3, site 2, modified residue 2, topological domain 2, splice variant 2, region of interest 2, signal peptide 1, chain 1, compositionally biased region 1, active site 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13443-F1	76.14	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 348; 56–57 (cleavage); 205–206 (cleavage; by furin-like protease)

Ligand- & substrate-binding residues (3): 347; 351; 357

Post-translational modifications (2): 758, 761

Disulfide bonds (7): 322–401, 363–385, 365–370, 473–493, 644–656, 650–662, 664–673

Glycosylation sites (6): 125, 144, 154, 231, 381, 487

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1442490	Collagen degradation
R-HSA-1474228	Degradation of the extracellular matrix
R-HSA-1474244	Extracellular matrix organization

MSigDB gene sets: 490 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, MODULE_172, AHRARNT_01, MODULE_52, GOBP_EPITHELIUM_DEVELOPMENT, TAATAAT_MIR126, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_RESPONSE_TO_CORTICOSTEROID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, MODULE_64

GO Biological Process (27): membrane protein ectodomain proteolysis (GO:0006509), cell adhesion (GO:0007155), cell-matrix adhesion (GO:0007160), transforming growth factor beta receptor signaling pathway (GO:0007179), integrin-mediated signaling pathway (GO:0007229), response to manganese ion (GO:0010042), cell migration (GO:0016477), protein processing (GO:0016485), keratinocyte differentiation (GO:0030216), positive regulation of cell migration (GO:0030335), membrane protein intracellular domain proteolysis (GO:0031293), cell adhesion mediated by integrin (GO:0033627), positive regulation of cell adhesion mediated by integrin (GO:0033630), cell-cell adhesion mediated by integrin (GO:0033631), positive regulation of macrophage fusion (GO:0034241), response to tumor necrosis factor (GO:0034612), monocyte activation (GO:0042117), response to hydrogen peroxide (GO:0042542), amyloid precursor protein catabolic process (GO:0042987), positive regulation of MAPK cascade (GO:0043410), positive regulation of protein secretion (GO:0050714), positive regulation of membrane protein ectodomain proteolysis (GO:0051044), response to glucocorticoid (GO:0051384), positive regulation of keratinocyte migration (GO:0051549), response to calcium ion (GO:0051592), cellular response to lipopolysaccharide (GO:0071222), proteolysis (GO:0006508)

GO Molecular Function (12): metalloendopeptidase activity (GO:0004222), protein kinase C binding (GO:0005080), integrin binding (GO:0005178), collagen binding (GO:0005518), metallopeptidase activity (GO:0008237), SH3 domain binding (GO:0017124), laminin binding (GO:0043236), metal ion binding (GO:0046872), metalloendopeptidase activity involved in amyloid precursor protein catabolic process (GO:1902945), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (8): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), focal adhesion (GO:0005925), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), extracellular exosome (GO:0070062), extracellular region (GO:0005576), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Degradation of the extracellular matrix	1
Extracellular matrix organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
membrane protein proteolysis	2
cell adhesion mediated by integrin	2
protein-containing complex binding	2
cellular process	1
cell-substrate adhesion	1
cellular response to transforming growth factor beta stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
cell surface receptor signaling pathway	1
response to metal ion	1
cell motility	1
proteolysis	1
protein maturation	1
epidermal cell differentiation	1
skin development	1
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
cell adhesion	1
regulation of cell adhesion mediated by integrin	1
positive regulation of cell adhesion	1
cell-cell adhesion	1
macrophage fusion	1
regulation of macrophage fusion	1
positive regulation of syncytium formation by plasma membrane fusion	1
response to cytokine	1
myeloid leukocyte activation	1
response to reactive oxygen species	1
amyloid precursor protein metabolic process	1
MAPK cascade	1
regulation of MAPK cascade	1
positive regulation of intracellular signal transduction	1
endopeptidase activity	1
metallopeptidase activity	1
protein kinase binding	1
signaling receptor binding	1
cell adhesion molecule binding	1
peptidase activity	1
protein domain specific binding	1
protein binding	1

Protein interactions and networks

STRING

1228 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADAM9	SNX9	Q9Y5X1	967
ADAM9	MAD2L2	Q9UI95	859
ADAM9	MAD2L1	Q13257	711
ADAM9	APP	P05067	691
ADAM9	PACSIN3	Q9UKS6	681
ADAM9	SH3GL2	Q99962	678
ADAM9	GP6	Q9HCN6	659
ADAM9	CLEC1B	Q9P126	640
ADAM9	ADAM17	P78536	633
ADAM9	SELP	P16109	632
ADAM9	PITPNM3	Q9BZ71	629
ADAM9	ADAM10	O14672	627
ADAM9	RPGRIP1	Q96KN7	615
ADAM9	RAX2	Q96IS3	613
ADAM9	EGF	P01133	611

IntAct

136 interactions, top by confidence:

A	B	Type	Score
VEGFD	ADAM9	psi-mi:“MI:0914”(association)	0.640
CRIPTO	AIP	psi-mi:“MI:0914”(association)	0.640
SNX9	WASL	psi-mi:“MI:0914”(association)	0.640
MAD2L2	ADAM9	psi-mi:“MI:0915”(physical association)	0.630
ADAM9	SNX9	psi-mi:“MI:0407”(direct interaction)	0.590
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
ADAM9	SNX18	psi-mi:“MI:0407”(direct interaction)	0.560
GPHA2	PLXNA2	psi-mi:“MI:0914”(association)	0.530
CD1B	TOR1B	psi-mi:“MI:0914”(association)	0.530
SCGB1D4	EGFR	psi-mi:“MI:0914”(association)	0.530
	PLOD2	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
ADGRG5	KLRG2	psi-mi:“MI:0914”(association)	0.530
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
CRP	QSOX1	psi-mi:“MI:0914”(association)	0.530
TMX1	NRP1	psi-mi:“MI:0914”(association)	0.530
INSL5	COCH	psi-mi:“MI:0914”(association)	0.530
OCLN	DNAJC13	psi-mi:“MI:0914”(association)	0.530
EPPIN	UMPS	psi-mi:“MI:0914”(association)	0.530
TIMP3	ZZEF1	psi-mi:“MI:0914”(association)	0.530

BioGRID (191): ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Co-fractionation), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-Western), ADAM9 (Affinity Capture-Western), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS), ADAM9 (Affinity Capture-MS)

ESM2 similar proteins: O35674, O43184, O43506, O75173, O88839, O95450, P57110, P58459, P59384, P59511, P70505, P78325, P79331, P97857, Q05910, Q13443, Q13444, Q14114, Q1EHB3, Q4VC17, Q5RFQ8, Q60813, Q61072, Q61824, Q62179, Q64151, Q68SA9, Q69Z28, Q8BNJ2, Q8C9W3, Q8TE57, Q8TE58, Q8TE60, Q8WXS8, Q924X6, Q9ESP7, Q9H013, Q9H324, Q9JI76, Q9JLN6

Diamond homologs: A0A0B4U9L8, A0A6B7FMR5, A2CJE2, A2CJE3, A2CJE4, A3R0T9, A4PBQ9, A8QL48, A8QL49, A8QL59, B8K1W0, C0LZJ5, C5H5D1, C5H5D2, C5H5D3, C5H5D4, C5H5D5, C5H5D6, C9E1R8, C9E1S0, D3TTC1, D3TTC2, D5LMJ3, D6PXE8, D8VNS0, F8RKV9, F8RKW0, F8RKW1, F8S108, G5EFD5, J3S829, J3S830, J3SDW6, J3SDW8, O35227, O35674, O42138, O43184, O77780, O88839

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ADAM9	“down-regulates quantity by destabilization”	FGFR2	cleavage
MMP14	“down-regulates quantity by destabilization”	ADAM9	cleavage

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 156 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metal ion SLC transporters	5	31.0×	6e-05
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	5	26.8×	6e-05
Downstream signal transduction	5	19.6×	2e-04
Signaling by SCF-KIT	6	15.4×	1e-04
NCAM signaling for neurite out-growth	5	14.0×	6e-04
R-HSA-425366	5	9.3×	2e-03
Clathrin-mediated endocytosis	8	7.0×	5e-04
Cargo recognition for clathrin-mediated endocytosis	6	6.5×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
zinc ion transmembrane transport	5	25.4×	7e-04
T cell receptor signaling pathway	7	7.7×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

599 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	23
Likely pathogenic	9
Uncertain significance	259
Likely benign	220
Benign	29

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1184447	NM_003816.3(ADAM9):c.1588_1591+10del	Pathogenic
1410127	NM_003816.3(ADAM9):c.543_546dup (p.Glu183fs)	Pathogenic
1452105	NM_003816.3(ADAM9):c.1420C>T (p.Arg474Ter)	Pathogenic
1804635	NM_003816.3(ADAM9):c.17_18del (p.Arg6fs)	Pathogenic
1879709	NC_000008.11:g.39018852GA[1]	Pathogenic
189795	NM_003816.3(ADAM9):c.1396-2A>G	Pathogenic
2134415	NM_003816.3(ADAM9):c.1284_1285del (p.Cys428_Asp429delinsTer)	Pathogenic
2424769	NC_000008.10:g.(?38911980)(38928942_?)del	Pathogenic
2798666	NM_003816.3(ADAM9):c.399T>A (p.Cys133Ter)	Pathogenic
2811859	NM_003816.3(ADAM9):c.1802G>A (p.Trp601Ter)	Pathogenic
3068523	NM_003816.3(ADAM9):c.702del (p.Ala234_Val235insTer)	Pathogenic
3069202	NM_003816.3(ADAM9):c.1189A>T (p.Lys397Ter)	Pathogenic
3245572	NC_000008.10:g.(?38913076)(38928942_?)del	Pathogenic
3248796	NM_003816.3(ADAM9):c.2020G>T (p.Glu674Ter)	Pathogenic
3727419	NM_003816.3(ADAM9):c.735C>A (p.Tyr245Ter)	Pathogenic
373092	NM_003816.3(ADAM9):c.196-1G>A	Pathogenic
6876	NM_003816.3(ADAM9):c.1130+1G>A	Pathogenic
6877	NM_003816.3(ADAM9):c.766C>T (p.Arg256Ter)	Pathogenic
6878	NM_003816.3(ADAM9):c.490C>T (p.Arg164Ter)	Pathogenic
6879	NM_003816.3(ADAM9):c.411-8A>G	Pathogenic
812214	NM_003816.3(ADAM9):c.1455C>A (p.Tyr485Ter)	Pathogenic
862925	NM_003816.3(ADAM9):c.1968T>A (p.Cys656Ter)	Pathogenic
915360	NM_003816.3(ADAM9):c.639T>G (p.Tyr213Ter)	Pathogenic
1065690	NM_003816.3(ADAM9):c.576del (p.Glu193fs)	Likely pathogenic
2013020	NM_003816.3(ADAM9):c.254+1G>A	Likely pathogenic
2034457	NM_003816.3(ADAM9):c.744+1G>A	Likely pathogenic
3242299	GRCh37/hg19 8p11.22(chr8:38933032-38935086)x1	Likely pathogenic
3248895	NM_003816.3:c.(672+1_673-1)_(914+1_915-1)del	Likely pathogenic
3341288	NM_003816.3(ADAM9):c.1698-1715_1881+156del	Likely pathogenic
3382263	NM_003816.3(ADAM9):c.103C>T (p.Gln35Ter)	Likely pathogenic

SpliceAI

3516 predictions. Top by Δscore:

Variant	Effect	Δscore
8:39007881:TGTA:T	acceptor_loss	1.0000
8:39007882:GTAG:G	acceptor_loss	1.0000
8:39007883:TA:T	acceptor_loss	1.0000
8:39007884:A:AG	acceptor_gain	1.0000
8:39007884:A:C	acceptor_loss	1.0000
8:39007884:AG:A	acceptor_gain	1.0000
8:39007885:G:GA	acceptor_gain	1.0000
8:39007885:GG:G	acceptor_gain	1.0000
8:39007885:GGCT:G	acceptor_gain	1.0000
8:39007979:AACAA:A	donor_gain	1.0000
8:39007980:ACAA:A	donor_gain	1.0000
8:39007981:CAA:C	donor_gain	1.0000
8:39007982:AA:A	donor_gain	1.0000
8:39007983:AG:A	donor_loss	1.0000
8:39007984:G:GG	donor_gain	1.0000
8:39007985:TAAG:T	donor_loss	1.0000
8:39011717:G:GG	donor_gain	1.0000
8:39013960:TCCA:T	acceptor_loss	1.0000
8:39013963:A:AG	acceptor_gain	1.0000
8:39013964:G:GG	acceptor_gain	1.0000
8:39013964:GA:G	acceptor_gain	1.0000
8:39013964:GAGA:G	acceptor_gain	1.0000
8:39013964:GAGAC:G	acceptor_gain	1.0000
8:39014043:GGTAA:G	donor_loss	1.0000
8:39014044:G:GG	donor_gain	1.0000
8:39014044:GTA:G	donor_loss	1.0000
8:39014045:T:A	donor_loss	1.0000
8:39017188:A:AG	acceptor_gain	1.0000
8:39017190:A:AG	acceptor_gain	1.0000
8:39017190:AATTT:A	acceptor_gain	1.0000

AlphaMissense

5385 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:39025852:T:A	C322S	1.000
8:39025853:G:A	C322Y	1.000
8:39025853:G:C	C322S	1.000
8:39026719:C:G	H347D	1.000
8:39026731:C:G	H351D	1.000
8:39026733:T:A	H351Q	1.000
8:39026733:T:G	H351Q	1.000
8:39041960:T:G	F382C	1.000
8:39055751:T:A	C524S	1.000
8:39055751:T:C	C524R	1.000
8:39055752:G:C	C524S	1.000
8:39055753:T:G	C524W	1.000
8:39077238:T:A	C570S	1.000
8:39077239:G:C	C570S	1.000
8:39077253:T:A	C575S	1.000
8:39077253:T:C	C575R	1.000
8:39077254:G:C	C575S	1.000
8:39023274:G:C	R288P	0.999
8:39025829:G:A	G314E	0.999
8:39025837:T:C	F317L	0.999
8:39025839:T:A	F317L	0.999
8:39025839:T:G	F317L	0.999
8:39025852:T:C	C322R	0.999
8:39025853:G:T	C322F	0.999
8:39025854:T:G	C322W	0.999
8:39025871:G:A	G328D	0.999
8:39026717:C:A	A346D	0.999
8:39026719:C:A	H347N	0.999
8:39026721:T:A	H347Q	0.999
8:39026721:T:G	H347Q	0.999

dbSNP variants (sampled 300 via entrez): RS1000007634 (8:39034243 A>G), RS1000037804 (8:39043965 G>A), RS1000075484 (8:39027502 G>C), RS1000093763 (8:39037097 C>T), RS1000120761 (8:39012196 C>T), RS1000152181 (8:39094300 T>C), RS1000159195 (8:39008517 T>C), RS1000192352 (8:39050830 G>T), RS1000245064 (8:39081848 A>C,G), RS1000247532 (8:39044929 T>C,G), RS1000260842 (8:39050734 G>C), RS1000313450 (8:39001959 C>T), RS1000316031 (8:39102860 A>T), RS1000325868 (8:39045464 G>A,C), RS1000326716 (8:39096340 A>T)

Disease associations

OMIM: gene MIM:602713 | disease phenotypes: MIM:612775, MIM:120970, MIM:615033, MIM:268000

GenCC curated gene-disease

Disease	Classification	Inheritance
cone-rod dystrophy 9	Definitive	Autosomal recessive
cone-rod dystrophy	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
ADAM9-related retinopathy	Definitive	AR

Mondo (5): inherited retinal dystrophy (MONDO:0019118), cone-rod dystrophy 9 (MONDO:0013002), cone-rod dystrophy (MONDO:0015993), hereditary spastic paraplegia 54 (MONDO:0014018), retinitis pigmentosa (MONDO:0019200)

Orphanet (4): OBSOLETE: Inherited retinal disorder (Orphanet:71862), Cone rod dystrophy (Orphanet:1872), Autosomal recessive spastic paraplegia type 54 (Orphanet:320380), Retinitis pigmentosa (Orphanet:791)

HPO phenotypes

17 total (18 of 17 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000505	Visual impairment
HP:0000529	Progressive visual loss
HP:0000543	Optic disc pallor
HP:0000548	Cone/cone-rod dystrophy
HP:0000551	Color vision defect
HP:0000603	Central scotoma
HP:0000613	Photophobia
HP:0000639	Nystagmus
HP:0000662	Nyctalopia
HP:0001105	Retinal atrophy
HP:0007641	Dyschromatopsia
HP:0007703	Abnormal retinal pigmentation
HP:0007737	Spicular pigmentation of the retina
HP:0007843	Attenuation of retinal blood vessels
HP:0012508	Metamorphopsia
HP:0030466	Abnormal full-field electroretinogram
HP:0000556	Retinal dystrophy

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002379_117	Basophil count	1.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005090	basophil count

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D000071700	Cone-Rod Dystrophies	C11.270.152; C11.768.585.658.250; C16.320.290.152
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5982 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 38,415 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL19611	ILOMASTAT	2	12,065
CHEMBL206815	APRATASTAT	2	256
CHEMBL296588	PEPSTATIN	2	26,094

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M12: Astacin/Adamalysin

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
ilomastat	Inhibition	9.0	pIC50

Binding affinities (BindingDB)

13 measured of 19 human assays (19 total across all organisms); most potent 13 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(2S)-N-hydroxy-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]-2-(4-methylsulfonylpiperazin-1-yl)propanamide	IC50	21 nM	US-8633196: Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
(2S)-N-hydroxy-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]-2-(4-propan-2-ylsulfonylpiperazin-1-yl)propanamide	IC50	33 nM	US-8633196: Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
(2S)-2-(4-ethylpiperazin-1-yl)-N-hydroxy-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]propanamide	IC50	41 nM	US-8633196: Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
(2S)-N-hydroxy-2-[4-(2-methylpropanoyl)piperazin-1-yl]-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]propanamide	IC50	53 nM	US-8633196: Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
(2S)-N-hydroxy-2-[4-[(4-methylphenyl)methyl]piperazin-1-yl]-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]propanamide	IC50	63 nM	US-8633196: Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
(2S)-2-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]-N-hydroxy-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]propanamide	IC50	67 nM	US-8633196: Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide	IC50	71 nM	US-9115102: N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors
(S)-N-hydroxy-4-(4-(4-hydroxybut-2-ynyloxy)phenylsulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide	IC50	71 nM	US-9266848: 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases
(2S)-N-hydroxy-2-[4-(2-methylpropylsulfonyl)piperazin-1-yl]-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]propanamide	IC50	86 nM	US-8633196: Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
4-but-2-ynoxy-N-[(2S)-3-(hydroxyamino)-2-(4-methylsulfonylpiperazin-1-yl)-3-oxopropyl]benzamide	IC50	942 nM	US-9115102: N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors
N-[(2S)-3-(hydroxyamino)-3-oxo-2-piperidin-1-ylpropyl]-4-(pyridin-4-ylmethoxy)benzamide	IC50	3090 nM	US-9266848: 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases
N-[(2S)-3-(hydroxyamino)-2-(4-methylsulfonylpiperazin-1-yl)-3-oxopropyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide	IC50	5800 nM	US-9115102: N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors
N-[(2S)-3-(hydroxyamino)-3-oxo-2-piperidin-1-ylpropyl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide	IC50	6400 nM	US-9266848: 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases

ChEMBL bioactivities

46 potent at pChembl≥5 of 48 total, top 45 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.00	IC50	1	nM	ILOMASTAT
7.25	IC50	56.3	nM	PEPSTATIN
7.25	IC50	56.3	nM	ILOMASTAT
7.16	IC50	70	nM	CHEMBL170315
7.16	IC50	70	nM	CHEMBL353536
7.07	IC50	85	nM	CHEMBL3392650
7.07	IC50	85	nM	APRATASTAT
7.05	IC50	90	nM	CHEMBL4215407
6.75	IC50	180	nM	CHEMBL173027
6.72	IC50	190	nM	CHEMBL171962
6.64	IC50	230	nM	CHEMBL366478
6.58	IC50	260	nM	CHEMBL355797
6.52	IC50	300	nM	CHEMBL172885
6.43	IC50	370	nM	CHEMBL172548
6.37	IC50	430	nM	CHEMBL173235
6.32	IC50	480	nM	CHEMBL4208519
6.29	IC50	510	nM	CHEMBL368857
6.28	IC50	520	nM	CHEMBL173316
6.25	IC50	560	nM	CHEMBL177072
6.18	IC50	660	nM	CHEMBL436049
6.18	IC50	660	nM	CHEMBL173686
6.16	IC50	700	nM	CHEMBL175164
6.10	IC50	800	nM	CHEMBL172249
6.09	IC50	810	nM	CHEMBL368205
6.08	IC50	830	nM	CHEMBL172415
6.05	IC50	890	nM	CHEMBL367710
6.04	IC50	910	nM	CHEMBL172722
5.97	IC50	1060	nM	CHEMBL173326
5.94	IC50	1140	nM	CHEMBL171292
5.87	IC50	1340	nM	CHEMBL173846
5.80	IC50	1600	nM	CHEMBL170429
5.78	IC50	1670	nM	CHEMBL425316
5.72	IC50	1890	nM	CHEMBL172886
5.71	IC50	1960	nM	CHEMBL539171
5.66	Ki	2200	nM	CHEMBL497985
5.65	IC50	2240	nM	CHEMBL173744
5.58	IC50	2600	nM	CHEMBL171986
5.51	IC50	3110	nM	CHEMBL174315
5.51	IC50	3054	nM	CHEMBL3648903
5.49	IC50	3251	nM	CHEMBL3704903
5.45	IC50	3560	nM	CHEMBL173754
5.07	IC50	8448	nM	CHEMBL4873384
5.03	IC50	9254	nM	CHEMBL3648902
5.00	IC50	1e+04	nM	GRASSYSTATIN A
5.00	Ki	1e+04	nM	CHEMBL1078396

PubChem BioAssay actives

40 with measured affinity, of 62 total; 39 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R)-N’-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide	241656: In vitro inhibition of A disintegrin and metalloprotease domain 9 (ADAM9)	ic50	0.0010	uM
(3S,4S)-3-hydroxy-4-[[(2S)-2-[[(3S,4S)-3-hydroxy-6-methyl-4-[[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanoyl]amino]propanoyl]amino]-6-methylheptanoic acid	448178: Inhibition of ADAM9	ic50	0.0563	uM
N-hydroxy-2-[methoxy-(4-methoxyphenyl)phosphoryl]-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.0700	uM
2-[ethoxy-[4-(2-ethoxyethoxy)phenyl]phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.0700	uM
N-hydroxy-3-[methyl-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]-1-(2-methylpropanoyl)azetidine-3-carboxamide	1371964: Inhibition of ADAM9 (unknown origin)	ic50	0.0900	uM
N-hydroxy-2-[(4-methoxyphenyl)-(2-pyridin-2-ylethoxy)phosphoryl]-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.1800	uM
7-amino-2-[ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.1900	uM
2-[ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.2300	uM
2-[ethoxy-(4-phenoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.2600	uM
2-[ethoxy-(4-fluorophenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.3000	uM
2-[ethoxy(phenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.3700	uM
benzyl 4-[ethoxy-(4-methoxyphenyl)phosphoryl]-3-(hydroxycarbamoyl)piperazine-1-carboxylate	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.4300	uM
N-hydroxy-1-(3-methylbutanoyl)-3-[methyl-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]azetidine-3-carboxamide	1371964: Inhibition of ADAM9 (unknown origin)	ic50	0.4800	uM
2-[2-ethoxyethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.5100	uM
5-[ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridine-6-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.5200	uM
6-[ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-7,8-dihydro-5H-pyrido[3,4-b]pyrazine-7-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.5600	uM
2-[ethoxy-(4-pyridin-4-yloxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.6600	uM
2-[(4-aminophenyl)-ethoxyphosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.6600	uM
2-[ethoxy(2-phenylethyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.7000	uM
2-[ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.8000	uM
2-[butoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.8100	uM
2-[ethoxy-(3-fluorophenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.8300	uM
2-[ethoxy(thiophen-2-yl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.8900	uM
2-[ethoxy-[(E)-2-phenylethenyl]phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	0.9100	uM
2-[ethoxy-(2-fluorophenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	1.0600	uM
2-[2-(diethylamino)ethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	1.1400	uM
2-[cyclohexylmethoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	1.3400	uM
2-[hexoxy-(4-methoxyphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	1.6000	uM
2-[[4-(4-aminophenoxy)phenyl]-ethoxyphosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	1.6700	uM
2-[ethoxy-(4-methylphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	1.8900	uM
2-[ethoxy-(4-phenylphenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	1.9600	uM
(6S,7S)-N-hydroxy-5-methyl-6-[4-[5-(trifluoromethyl)-2-pyridinyl]piperazine-1-carbonyl]-5-azaspiro[2.5]octane-7-carboxamide	1356429: Inhibition of recombinant human C-terminal His10-tagged ADAM9 (Ala206 to Asp697 residues) expressed in mouse cells using McaPLAQAV-Dpa-RSSSR-NH2 as substrate by fluorescence spectrophotometric method	ki	2.2000	uM
N-hydroxy-2-[(4-methoxyphenyl)-propan-2-yloxyphosphoryl]-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	2.2400	uM
2-[ethoxy(pyridin-4-yl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	2.6000	uM
N-hydroxy-2-[(4-methoxyphenyl)-(2-phenylethoxy)phosphoryl]-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	3.1100	uM
N-hydroxy-2-[(4-methoxyphenyl)-[2-(4-phenylphenyl)ethoxy]phosphoryl]-3,4-dihydro-1H-isoquinoline-3-carboxamide	66433: Inhibition of the heparin binding epidermal growth factor (HB-EGF) release from fibrosarcoma HT1080 transfectants expressing alkaline phosphate (AP) tagged HB-EGF stimulated by 12-O-tetradecanoylphorbol 13-acetate(TPA).	ic50	3.5600	uM
(5R)-5-[3-[4-(3,5-dichlorophenyl)piperazin-1-yl]-3-oxopropyl]imidazolidine-2,4-dione	1775686: Inhibition of ADAM-9 (unknown origin)	ic50	8.4480	uM
5-[(5-methoxy-3-oxo-1H-indazol-2-yl)methyl]-5-methylimidazolidine-2,4-dione	464407: Inhibition of ADAM9	ki	10.0000	uM
methyl (2S)-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-2-[[(3S,4S)-4-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[(2S)-2-[(2S)-2-(dimethylamino)-3-methylbutanoyl]oxy-3-methylbutanoyl]oxy-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]-methylamino]-3-phenylpropanoyl]pyrrolidine-2-carboxylate	448855: Inhibition of ADAM9 after 10 to 15 mins by fluorescence assay	ic50	10.0000	uM

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Hydrogen Peroxide	decreases reaction, increases expression, affects expression	3
mercuric bromide	affects cotreatment, increases expression	2
Resveratrol	affects cotreatment, increases expression	2
Lead	affects expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Dihydrotestosterone	increases expression, decreases reaction, affects reaction	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	affects localization, increases expression	2
Valproic Acid	increases expression	2
tert-Butylhydroperoxide	decreases reaction, increases expression, affects cotreatment, affects expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
sodium arsenate	increases expression	1
sodium arsenite	decreases expression	1
sulindac sulfide	decreases expression	1
benazol P	affects expression	1
aluminum sulfate	decreases expression	1
ebselen	decreases reaction, increases expression	1
bicalutamide	increases expression, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Rosiglitazone	affects cotreatment, increases expression, decreases reaction	1
Pioglitazone	decreases reaction, increases expression	1
Fulvestrant	increases methylation	1

ChEMBL screening assays

19 unique, capped per target: 18 binding, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1039217	Binding	Inhibition of ADAM9 assessed as residual activity at 10 uM after 10 to 15 mins by fluorescence assay relative to control	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. — J Med Chem
CHEMBL4186131	ADMET	Inhibition of ADAM9 (unknown origin)	Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis. — Bioorg Med Chem

Cellosaurus cell lines

9 cell lines: 6 cancer cell line, 2 transformed cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1J0	Abcam HeLa ADAM9 KO	Cancer cell line	Female
CVCL_D7JL	Ubigene A-549 ADAM9 KO	Cancer cell line	Male
CVCL_D8YQ	Ubigene HEK293 ADAM9 KO	Transformed cell line	Female
CVCL_E6P0	Genomeditech CHO-K1 H_ADAM9	Spontaneously immortalized cell line	Female
CVCL_E6TB	Genomeditech HEK-293 H_ADAM9	Transformed cell line	Female
CVCL_SB49	HAP1 ADAM9 (-) 1	Cancer cell line	Male
CVCL_SB50	HAP1 ADAM9 (-) 2	Cancer cell line	Male
CVCL_SB51	HAP1 ADAM9 (-) 3	Cancer cell line	Male
CVCL_SB52	HAP1 ADAM9 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

263 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT05902962	PHASE1	COMPLETED	SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
NCT06319872	PHASE1	RECRUITING	The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration